LAG3 and neoplasm: Additionally, early-stage clinical data suggest improved anti-tumour response in MSS CRC patients treated with favezelimab (anti-LAG-3) plus pembrolizumab (anti-PD-1), versus pembrolizumab monotherapy (objective response rate [ORR] 6.3% [n = 5/80] versus 0% [n = 0/20], respectively) [23].